SCHEMBL1026299

SCHEMBL1026299

O=C(O)c1ccccc1Nc1ccnc(C(F)(F)F)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS2R14 Q9NYV8 12/20 0.64
MAPK8 P45983 3/20 0.56
AURKA O14965 1/20 0.56
FABP4 P15090 1/20 0.51
PTGS1 P23219 1/20 0.51
PTGS2 P35354 1/20 0.51
AKR1C3 P42330 1/20 0.51
AKR1C2 P52895 1/20 0.51
ADRA2B P18089 1/20 0.51
ADRA2C P18825 1/20 0.51
DAPK3 O43293 1/20 0.50
JAK2 O60674 1/20 0.50
PRKD3 O94806 1/20 0.50
PIM1 P11309 1/20 0.50
PRKACA P17612 1/20 0.50
CDK2 P24941 1/20 0.50
FLT3 P36888 1/20 0.50
CSNK1A1 P48729 1/20 0.50
CDK8 P49336 1/20 0.50
CLK2 P49760 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31237569 0.79 TP53 (0.47) TAS2R14
SCHEMBL31237571 0.78 KMT2A (0.45) TAS2R14MAPK8DYRK1A
Flufenamic Acid SCHEMBL29356958 0.76 RXFP1 (0.75) TAS2R14MAPK8AURKAPTGS1PTGS2
Flufenamic Acid SCHEMBL17497 0.76 RXFP1 (0.75) TAS2R14MAPK8AURKAPTGS1PTGS2
SCHEMBL11330727 0.76 TAS2R14 (0.82) TAS2R14FABP4AKR1C3AKR1C2ADRA2B
Flufenamic Acid SCHEMBL9845499 0.75 RXFP1 (0.73) TAS2R14MAPK8AURKAPTGS1PTGS2
Flufenamic Acid SCHEMBL11524554 0.75 RXFP1 (0.73) TAS2R14MAPK8AURKAPTGS1PTGS2
SCHEMBL29417535 0.75 MAPT (0.51) TAS2R14FABP4PTGS1PTGS2AKR1C3
SCHEMBL10186488 0.75 FABP4 (0.71) TAS2R14MAPK8AURKAFABP4PTGS1
SCHEMBL8708722 0.74 SMARCA2 (0.72) PIM1FLT3CDK9CLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8309726-B2 Substituted piperazine compounds of formula 8 COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2012-11-13 US disclosed
EP-2150527-B1 ANTHRANILIC ACID DERIVATIVE AS ANTICANCER AGENT AND A PROCESS FOR THE PREPARATION THEREOF COUNCIL SCIENT IND RES (IN) 2011-01-19 EP disclosed
US-20100016589-A1 Novel Anthranilic Acid Derivative as Potential Anticancer Agent and a Process for the Preparation Thereof COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2010-01-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016589-A1 Novel Anthranilic Acid Derivative as Potential Anticancer Agent and a Process for the Preparation Thereof AADAC, API5, APEH TAS2R14 3591/4885MAPK8 233/4885AURKA 49/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.